Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
June 2013
Features
Biosimilars
Part 2: Potential Concerns and Challenges for P&T Committees
P&T committee members need a lot more information before they can evaluate the efficacy and safety, interchangeability, and cost-effectiveness of biosimilar products for inclusion on formularies.
C. Lee Ventola, MS
Polycystic Ovary Syndrome
A Review of Treatment Options With a Focus on Pharmacological Approaches
Oral contraceptives, antidiabetes drugs, and statins are some of the therapies used to address the symptoms of this complex hormonal condition. Weight loss and surgery may also be beneficial as non-drug options.
Uche Anadu Ndefo, PharmD, BCPS; Angie Eaton, PharmD; and Monica Robinson Green, PharmD, BCPS, BCACP
Pharmacovigilance Forum
Drug-Induced Pancreatitis
A Potentially Serious and Underreported Problem
There have been many published reports of possible cases of drug-induced pancreatitis. In addition, some disease states and patient characteristics predispose particular populations to the development of this condition. Three case histories are presented.
Michele B. Kaufman, PharmD, RPh
Meeting Highlights
48th European Association for the Study of the Liver and American Association for Cancer Research
Therapies for hepatitis C include sofosbuvir; an interferon-free triple regimen; and an investigational agent, MK-5172. Ramucirumab for gastric and gastroesophageal junction cancers and an everolimus/exemestane combination for breast cancer are also discussed.
Walter Alexander
Departments
Medication Errors
Multiple Brand Names for the Same Generic Drug Can Cause Confusion
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Medicare Changes Include New Part D Rules and Possible Cuts to Hospitals
Stephen Barlas
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Pharmaceutical Approval Update
Extended-release carbinoxamine maleate oral suspension (Karbinal ER) for allergic rhinitis; brinzolamide 1.0%/brimonidine tartrate 0.2% ophthalmic suspension (Simbrinza) for open-angle glaucoma and ocular hypertension; and cysteamine bitartrate (Procysbi) for nephropathic cystinosis
Marvin M. Goldenberg, PhD, RPh, MS
Drug Forecast
Nuedexta for the Treatment of Pseudobulbar Affect
A Condition of Involuntary Crying or Laughing
Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect
Martin Paspe Cruz, PharmD, CGP, BCPP
